Vivus reports bigger-than-expected 4th-qtr loss

Mon Feb 25, 2013 4:21pm EST

Feb 25 (Reuters) - Vivus Inc's revenue for the first full quarter of selling its diet pill Qsymia fell short of analysts' estimates, and it posted a bigger-than-expected loss related to higher marketing expenses.

The company's fourth-quarter net loss rose to $56.7 million, or 56 cents per share, from $11.5 million, or 13 cents per share, a year earlier.

Net product revenue, reflecting sales of Qsymia, was $2 million in the fourth quarter, compared with $41,000 reported in the third quarter.

Vivus started generating revenue from the third quarter, when it began selling Qsymia.

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.